New Drugs for Non-Muscle-Invasive Bladder Cancer Offer Exciting Possibilities for High-Risk Patients

Originally published November 20, 2026

Last updated November 20, 2026

Reading Time: 4 minutes

Search more articles

News & Magazine

A picture of bladder cancer

A shortage of BCG has prompted new innovations for treating bladder cancer.

Over the last few decades, there’s been a shortage of Bacillus Calmette-Guérin (BCG), the immunotherapy treatment most common for patients with non-muscle-invasive bladder cancer.  

“For 50 years, BCG has essentially been the standard of care for non-muscle-invasive bladder cancer,” says Anne K. Schuckman, MD, a urologic oncologist with the USC Norris Comprehensive Cancer Center and USC Urology, part of Keck Medicine of USC. “There are, however, people who don’t respond well to BCG. The need to find alternative treatments for these patients has really pushed the field forward for researchers to develop alternate agents and pathways of treatment.” 

Dr. Schuckman stands in a white medical coat, smiling against a grey background
Anne K. Schuckman, MD

This has led to a huge number of new drugs available for use in clinical trials at large academic medical centers like Keck Medicine. Additionally, doctors are experimenting with using other drugs off-label to bring relief to patients, Schuckman says. 

“Historically, if patients didn’t respond to BCG, we had a couple of agents available that we could try, but they weren’t very effective and maybe had only a 20% chance of working,” she says. “We would try those, but if they didn’t work, then patients would usually need to have their bladder removed and potentially have a neobladder built or receive some other form of urinary diversion.” 

Today, several new medications are available to use off-label for non-muscle-invasive bladder cancer, such as a gemcitabine intravesical system (brand name Inlexzo), she explains. “People refer to Inlexzo as ‘the pretzel’ because it looks like a little pretzel that we put in a patient’s bladder that releases chemotherapy over time,” Schuckman says. Other alternative treatments include a gene therapy agent called nadofaragene firadenovec-vncg (brand name Adstiladrin) and other combinations of chemotherapy, the most popular of which is the combination of gemcitabine and docetaxel. All these drugs are used to treat patients who don’t respond upfront to BCG. All are inserted into the patient’s bladder. 

“The response rates are much better for these medications — between 70%-80% — and can allow more patients to keep their bladders,” Schuckman says. “This is a big change in the way we think about treating patients. We used to have to consider bladder removal right away if a patient didn’t respond to BCG, but now we have other drug options we can try that can work for years before a recurrence, allowing patients to avoid a cystectomy.”  

What are the benefits of referring patients to a specialty urology center for non-muscle-invasive bladder cancer?  

“Unfortunately, these drugs are all currently very expensive, and it can often be too expensive for private practices to administer them,” Schuckman says. “As an academic medical system, however, we have the resources to provide these medications to patients. Additionally, many of these agents require special handling or chemotherapy nurses, which we have here at Keck Medicine.”  

As a leader in the field, USC Urology has been a part of many of the clinical trials to develop these new drugs, Schuckman explains. “And it’s never too early to start thinking about novel therapies for non-muscle-invasive bladder cancer,” she adds.  

Once it’s determined that a patient doesn’t respond to BCG, that is a good time to consider either changing agents or referring the patient to a center that might have a wider availability of agents available, she says.  

“It’s a very different landscape than it was five years, or even two years ago,” Schuckman says. “Where in the past 30%-40% of patients might have ended up needing to have their bladder removed, now we’ve reduced that to about 20% of patients. And, as the safety profile of these new medications builds, I think we can reduce that number even more, which will make a meaningful difference for patients.”  

Future research needed for more personalized treatment 

The next frontier in research for non-muscle-invasive bladder cancer will be to determine which types of agents certain patients will respond best to, Schuckman says. “With the availability of all these new drugs, it’s on us to figure out which one is going to work the best for a patient,” she says. “It is increasingly important to determine which patients will be more or less likely to respond to a specific medication and to find genetic markers of susceptibility.” 

Another exciting development in the bladder cancer field is the use of circulating tumor DNA for diagnosis. “This method allows us to pick up small amounts of tumor potentially before we could find them with traditional imaging or other diagnostic modalities,” she says. “We’ve always been looking for a great urinary biomarker to allow us to pick up disease recurrence earlier, without having to do so much invasive testing through cystoscopy or biopsies. The development of urine tumor DNA assays will allow us to provide a better patient experience for people with non-muscle-invasive bladder cancer.” 

Refer a Patient

The pioneering care provided by Keck Medicine of USC physicians remains on the forefront of leading-edge medicine. Learn how our capabilities can help your toughest cases. 
Use Our Quick Referral Form

Topics

Mollie Barnes, a Digital Writer and Editor for Keck Medicine of USC.
Mollie Barnes
Mollie Barnes is a senior digital editor and writer with Keck Medicine of USC.

Search more articles

News & Magazine